Marc Labriffe
Overview
Explore the profile of Marc Labriffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sayadi H, Fromage Y, Labriffe M, Billat P, Codde C, Arraki Zava S, et al.
AAPS J
. 2025 Feb;
27(2):53.
PMID: 40021573
Introduction: Valganciclovir, a prodrug of ganciclovir (GCV), is used to prevent cytomegalovirus infection after transplantation, with doses adjusted based on creatinine clearance (CrCL) to target GCV AUC0-24 h of 40-60 ...
2.
Couderc S, Crepin S, Labriffe M, Monchaud C, Roussel H, Garnier A, et al.
Therapie
. 2025 Feb;
PMID: 40000276
No abstract available.
3.
Sayadi H, Fromage Y, Monchaud C, Languepin J, Masson-Rouchaud A, Labriffe M, et al.
Ther Drug Monit
. 2025 Feb;
47(2):189-192.
PMID: 39933065
Background: Ciprofloxacin (CIP) is effective against many Gram-negative pathogens and penetrates well into respiratory secretions and pulmonary tissues, thus making it useful for treating respiratory infections in patients with cystic...
4.
Fromage Y, Sayadi H, Koloskoff K, Marquet P, Labriffe M, Monchaud C, et al.
Br J Clin Pharmacol
. 2024 Dec;
PMID: 39710604
Aims: Mycophenolic acid (MPA), the active component of enteric-coated mycophenolate sodium (EC-MPS), exhibits highly variable pharmacokinetics. Only a few population pharmacokinetic (popPK) models and Bayesian estimators (MAP-BE) exist for estimating...
5.
Woillard J, Benoist C, Destere A, Labriffe M, Marchello G, Josse J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Oct;
14(1):82-94.
PMID: 39412034
The use of synthetic data in pharmacology research has gained significant attention due to its potential to address privacy concerns and promote open science. In this study, we implemented and...
6.
Piet J, Booth A, Donker E, De Ponti F, Lunghi C, Poluzzi E, et al.
Lancet Planet Health
. 2024 Sep;
8(10):e715-e716.
PMID: 39303730
No abstract available.
7.
Sayadi H, Fromage Y, Labriffe M, Danthu C, Monchaud C, Woillard J
Ther Drug Monit
. 2024 Sep;
PMID: 39264343
Background: Daptomycin's efficacy and toxicity are closely related to its exposure, which can vary widely among individuals. The patient, a 59-year-old male with an estimated glomerular filtration rate (eGFR) of...
8.
Ponthier L, Franck B, Autmizguine J, Labriffe M, Ovetchkine P, Marquet P, et al.
Antimicrob Agents Chemother
. 2024 Aug;
68(10):e0086024.
PMID: 39194260
Intravenous ganciclovir and oral valganciclovir display significant variability in ganciclovir pharmacokinetics, particularly in children. Therapeutic drug monitoring currently relies on the area under the concentration-time (AUC). Machine-learning (ML) algorithms represent...
9.
Rivals F, Goutelle S, Codde C, Garreau R, Ponthier L, Marquet P, et al.
Clin Pharmacokinet
. 2024 Jul;
63(8):1137-1146.
PMID: 39085523
Background And Objective: The dosage of daptomycin is usually based on body weight. However, it has been shown that this approach yields too high an exposure in obese patients. Pharmacokinetic...
10.
Couderc S, Crepin S, Labriffe M, Monchaud C, Roussel H, Garnier A, et al.
Therapie
. 2024 Jul;
79(6):730-736.
PMID: 38964941
No abstract available.